IDEAYA Showcases Darovasertib Data at ESMO 2026
SOUTH SAN FRANCISCO, Calif., July 17, 2026 IDEAYA Biosciences, Inc. has announced that it will present three clinical abstracts...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
SOUTH SAN FRANCISCO, Calif., July 17, 2026 IDEAYA Biosciences, Inc. has announced that it will present three clinical abstracts...
PARMA, ITALY & FRAMINGHAM, MASSACHUSETTS, April 29, 2026 Chiesi Group has announced a definitive agreement to acquire KalVista Pharmaceuticals...
SOUTH SAN FRANCISCO, CALIFORNIA, April 30, 2026 IDEAYA Biosciences has announced that the U.S. Food and Drug Administration (FDA)...
South San Francisco, California, USA, April 21, 2026 In a significant advancement in precision oncology, IDEAYA Biosciences, Inc. has...
South San Francisco, California | April 10, 2026 IDEAYA Biosciences has announced that it will disclose topline results from...
San Diego, USA & Suzhou, China, April 2, 2026 Strong Clinical Efficacy in MSS Colorectal Cancer In a major...
South San Francisco, California, USA, April 6, 2026 First-in-Class Epigenetic Therapy Enters Clinical Development In a major step forward...
South San Francisco, California, USA | March 22, 2026 IDEAYA Biosciences has announced updated guidance on the anticipated topline...
